A number of other equities analysts have also issued reports on ABZA. FinnCap reiterated a buy rating and issued a GBX 70 ($0.98) target price on shares of Abzena in a research report on Tuesday, November 21st. Numis Securities reiterated a buy rating and issued a GBX 80 ($1.12) target price on shares of Abzena in a research report on Wednesday, December 13th.
Abzena (LON ABZA) opened at GBX 25.52 ($0.36) on Thursday. The stock has a market cap of $54.57 and a PE ratio of -319.00. Abzena has a 12-month low of GBX 25 ($0.35) and a 12-month high of GBX 53 ($0.74).
Abzena plc is a life sciences company. The Company provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups.
Receive News & Ratings for Abzena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abzena and related companies with MarketBeat.com's FREE daily email newsletter.